

South Dakota Department of Social Services, Division of Medicaid Services Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, December 8, 2023

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Matthew Stanley, DO	X
Dana Darger, RPh, Chair	X	Deidra Van Gilder, PharmD, Chair	X
Bill Ladwig, RPh	X	Clarissa Barnes, MD, DSS Staff	X
Kelley Oehlke, PharmD	X	Mike Jockheck, DSS Staff	X
Lenny Petrik, PharmD	X	Taylor Koerner, DSS Staff	X
Heather Preuss, MD			

Darger Retirement

Secretary of Social Services Matt Althoff read the proclamation designating December 8 as Dana Darger Day. Darger has served on this committee since its inception 20 years ago. Darger said it was his honor to serve on this committee to help the community of South Dakota.

Administrative Business

Darger called the meeting to order at 1:08 pm and handed the position of chair to Van Gilder. Van Gilder assumed chair of the meeting. The minutes of the September meeting were presented. Baack made a motion to approve. Oehlke seconded the motion. The motion was unanimously approved.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from July 1, 2023, to September 30, 2023. A total of 2,416 PAs were reviewed of which 147 requests (6%) were received via telephone, 113 requests (4.7%) were received via fax, 846 (35%) were reviewed electronically, and 1,309 (54.2%) PAs were received via ePA. There was a 30.7% increase in PAs received compared to the previous quarter. This corresponded to an increase in ePA and phone requests. The phone requests had doubled since the previous quarter and for the first time exceeded the number of fax requests. The increase in phone requests was due to requests for brand Synthroid which was the result of terming the narrow therapeutic index drug list in July.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from July 1, 2023, to September 30, 2023. The top five therapeutic classes based on paid amount were atypical antipsychotics, disease-modifying anti-rheumatic agents, skin and mucous membrane agents, incretin mimetics, and cystic fibrosis correctors. These top 15 therapeutic classes comprise 23.8% of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 9.1% of total claims. The drug Daybue had the highest increase due to the increase in utilizers.

Old Business

PA Approval Comparison

The committee reviewed the PA approvals of South Dakota Medicaid and other Medicaid states. South Dakota Medicaid PA approvals are higher than the three other states for comparison. The other states

have lower approval rates since many of their requests are for non-formulary drug requests compared to a clinical PA review. Jockheck expressed reviewing those PA requests with low frequency or high approval rates for cleanup. Stanley inquired about the per member per month (PMPM) figure. Jockheck stated the average is \$72 PMPM and that expansion members would receive the same benefits. The PMPM comparison with other Medicaid states was requested for review.

Opioid update

The committee reviewed 3Q2023 opioid outcomes compared to previous quarters from the opioid initiatives. There was a decrease in opioid utilization and utilizers during 3Q2023 with corresponding decrease in total eligibility and utilizers. Ladwig inquired about calculating the decrease in MME over time. Stanley inquired about the change in hospitalization and/or deaths associated with opioids use. Baack noted experiencing less neonatal opioid withdrawal seen now.

New Business

Epidemiology Presentation

Angela Cascio, Infectious Disease Director from the South Dakota Department of Health, presented the Trending Epidemiology in South Dakota. The committee discussed current trends seen across the state. In addition, committee reviewed the hepatitis C PA approvals, number of patients treated, and utilization. Petrik asked how many still need treatment for hepatitis C. A review of denied claims compared to those who have been treated will be provided at the next meeting. Oehlke asked what the next steps are for treating members who may not know criteria has been expanded. DSS will explore options to notify providers.

Jornay PM & Stimulant review

The committee reviewed Jornay PM utilization. Stimulant utilization of members 21 years and older was also review compared to 4Q2020. Stimulant utilization of members taking immediate release (IR) and extended-release (ER) was also reviewed. Baack expressed concern for Jornay PM utilization in a 4-year-old member and concern for diversion. Stanley commented Vyvanse has a lower risk of diversion. Committee reviewed PA criteria of other states. Nicole Poppinga from Avera provided public comment. Stanley recommended adding PA on long-acting stimulants for children less than 6 years old unless written by a psychiatrist or behavioral specialist. After discussion, Baack made a motion to add PA to long-acting stimulants to try short acting first for children less than 6 years old unless seen by a psychiatrist or behavioral specialist. Darger seconded the motion. Van Gilder inquired if there was any public comment. There was none. The motion was approved unanimously.

FDA Advisory Letter on Stimulants

Ladwig provided commentary on the crisis seen with the ADHD shortages. Baack stated pandemic has heightened mental health concerns for children and this is going to continue to be a national issue.

Van Gilder inquired if there was any public comment. There were none.

Humira shift to Skyrizi

Committee reviewed analysis of the potential utilization shift from Humira to Skyrizi. There were none seen during the time frame reviewed.

Ilaris new indication

The committee reviewed the new indication for Ilaris for the symptomatic treatment of adult patients with gout flares and discussed adding PA criteria. Baack motioned removing the rheumatology consult

and proposed patients try NSAIDs and colchicine. Darger seconded the motion. Van Gilder inquired if there was any public comment. There was none. The motion was approved unanimously.

Nuzyra

Nuzyra clinical information was presented for review. Committee discussed adding criteria to Nuzyra. Darger made a motion to add PA criteria. Petrik seconded the motion. Van Gilder inquired if there was any public comment. There was none. The motion was approved unanimously.

Vowst

Vowst clinical information was presented for review. Committee discussed the merits of this drug. Baack recommended monitoring utilization.

Adjournment

The next meeting is scheduled on March 8, 2024. The June meeting is scheduled for June 7, 2024. Darger made the motion to adjourn the meeting and Petrik seconded the motion. The motion to adjourn the meeting was unanimous, and the meeting adjourned at 3:01 pm CT.

DRAFT